Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:DXMMQ NASDAQ:HAO OTCMKTS:INNI OTCMKTS:LPHM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXMMQDex Media$0.00$0.00▼$0.30$123KN/A119,053 shs5,800 shsHAOHaoxi Health Technology$0.96+8.5%$75.42$0.78▼$285.44$410K-1.361.17 million shs4.98 million shsINNIInnovaro$0.02$0.02$0.00▼$0.05$470K52.8438,221 shsN/ALPHMLee Pharmaceuticals$0.01+7.7%$0.06$0.01▼$0.40$492K669.9154,707 shs116,952 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXMMQDex Media0.00%0.00%0.00%0.00%0.00%HAOHaoxi Health Technology0.00%-15.74%-99.05%-99.39%-99.50%INNIInnovaro0.00%-12.92%+8.29%-8.73%+90.00%LPHMLee Pharmaceuticals0.00%+57.30%+102.90%+6,900.00%+6,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXMMQDex Media$0.00$0.00▼$0.30$123KN/A119,053 shs5,800 shsHAOHaoxi Health Technology$0.96+8.5%$75.42$0.78▼$285.44$410K-1.361.17 million shs4.98 million shsINNIInnovaro$0.02$0.02$0.00▼$0.05$470K52.8438,221 shsN/ALPHMLee Pharmaceuticals$0.01+7.7%$0.06$0.01▼$0.40$492K669.9154,707 shs116,952 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXMMQDex Media0.00%0.00%0.00%0.00%0.00%HAOHaoxi Health Technology0.00%-15.74%-99.05%-99.39%-99.50%INNIInnovaro0.00%-12.92%+8.29%-8.73%+90.00%LPHMLee Pharmaceuticals0.00%+57.30%+102.90%+6,900.00%+6,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXMMQDex Media 0.00N/AN/AN/AHAOHaoxi Health Technology 1.00SellN/AN/AINNIInnovaro 0.00N/AN/AN/ALPHMLee Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DXMMQ, LPHM, INNI, and HAO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026HAOHaoxi Health Technology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 6/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXMMQDex MediaN/AN/AN/AN/AN/AN/AHAOHaoxi Health Technology$32.80M0.01N/AN/A$1,727.58 per share0.00INNIInnovaroN/AN/AN/AN/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXMMQDex MediaN/AN/AN/AN/AN/AN/AN/AN/AN/AHAOHaoxi Health Technology$3.88MN/AN/AN/AN/AN/AN/AN/AN/AINNIInnovaroN/AN/AN/AN/AN/AN/AN/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXMMQDex MediaN/AN/AN/AN/AN/AHAOHaoxi Health TechnologyN/AN/AN/AN/AN/AINNIInnovaroN/AN/AN/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXMMQDex MediaN/AN/AN/AHAOHaoxi Health Technology0.023.45N/AINNIInnovaroN/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXMMQDex MediaN/AHAOHaoxi Health TechnologyN/AINNIInnovaroN/ALPHMLee PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipDXMMQDex MediaN/AHAOHaoxi Health TechnologyN/AINNIInnovaro3.30%LPHMLee Pharmaceuticals55.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXMMQDex Media2,96017.56 millionN/ANot OptionableHAOHaoxi Health Technology29460,000N/AN/AINNIInnovaro722.61 million21.87 millionNot OptionableLPHMLee Pharmaceuticals135.16 million15.82 millionNot OptionableDXMMQ, LPHM, INNI, and HAO HeadlinesRecent News About These CompaniesGan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist BofanglutideApril 9, 2026 | prnewswire.comGan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2March 31, 2026 | prnewswire.comOnce-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight ManagementNovember 27, 2025 | prnewswire.comGan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific SessionsJune 21, 2025 | prnewswire.comGan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or ObesityMarch 10, 2025 | prnewswire.comGan & Lee Pharmaceuticals divulges new antibody-drug conjugatesDecember 25, 2024 | bioworld.comBGan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two WeeksNovember 12, 2024 | prnewswire.comObesityWeek®? 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese AdultsNovember 11, 2024 | medindia.netMLongboard Pharmaceuticals (LBPH) Receives a Hold from Truist FinancialNovember 11, 2024 | markets.businessinsider.comObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese AdultsNovember 11, 2024 | prnewswire.comGan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical StudiesOctober 15, 2024 | prnewswire.comAssessing Longboard Pharmaceuticals’ Acquisition: Undervalued Potential Amidst Industry InterestOctober 14, 2024 | markets.businessinsider.comFTC Files Suit Against the Three Largest Pharmacy Benefit ManagersOctober 10, 2024 | jdsupra.comMat2A inhibitors reported in Gan & Lee Pharmaceuticals patentSeptember 27, 2024 | bioworld.comBGan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)September 14, 2024 | prnewswire.comAustin Lee ResourcingAugust 21, 2024 | pmlive.comPLee Health Embraces AI to Support Patient Care, Improve Health Outcomes, and Increase EfficiencyAugust 10, 2024 | smdailyjournal.comSFranklin Regional graduate Spencer Lee soars to semi-finals in Paris Olympics 57kg FreeStyleAugust 9, 2024 | msn.comGymnastics-Lee credits doctors and team for lifting her to Paris Olympic gloryAugust 6, 2024 | reuters.comGymnastics-Lee overcomes illness, criticism to return to Olympic podiumAugust 1, 2024 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026Manic Monday.com: The Rally Is Just the Beginning for this SaaS LeaderBy Thomas Hughes | May 11, 2026Cisco’s Vertical Rally May Still Be in the Early InningsBy Thomas Hughes | May 14, 2026Abercrombie Rallies as Strong Q1 Earnings Extend Winning StreakBy Jennifer Ryan Woods | May 27, 2026Axon Surged After Earnings and Is Still Down Over 50% From HighsBy Leo Miller | May 12, 2026DXMMQ, LPHM, INNI, and HAO Company DescriptionsDex Media OTCMKTS:DXMMQDex Media, Inc. is a provider of local marketing solutions to business clients across the United States. The Company's local marketing solutions are primarily sold under Dex and Super brands, including print yellow page directories, online local search engine Websites, mobile local search applications, and placement of its client's information and advertisements on search engine Websites, with, which the Company is affiliated. Its local marketing solutions also include Website development, search engine optimization, market analysis, video development and promotion, reputation management, social media marketing, and tracking and reporting of customer leads. Its print yellow page directories are co-branded with various local telephone service providers. The Company offers various solutions, such as DexHub, DexLnk, Social Media, Search Engine Optimization (SEO), Websites, Performance Tracking Program and Search Engine Marketing (SEM), among others.Haoxi Health Technology NASDAQ:HAO$0.96 +0.08 (+8.52%) Closing price 04:00 PM EasternExtended Trading$0.81 -0.15 (-15.63%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Haoxi Health Technology Limited, through its subsidiaries, provides online marketing solutions in China. It offers online marketing solutions, including online short video marketing solutions to advertisers through its media partners; and customized marketing solutions by planning, producing, placing, and optimizing online ads to help advertisers acquire, convert, and retain consumers on various online media platforms. The company places its ads through mainstream online short video and social media platforms, such as Toutiao, Douyin, WeChat, and Sina Weibo. It serves advertiser client base primarily in the healthcare industry. The company was founded in 2018 and is based in Beijing, China.Innovaro OTCMKTS:INNI$0.02 0.00 (0.00%) As of 06/5/2026Innovaro, Inc. does not have significant operations. The company plans to acquire an operating company through reverse merger. Previously, it was engaged in the provision of software services. The company was formerly known as UTEK Corporation and changed its name to Innovaro, Inc. in July 2010. Innovaro, Inc. was incorporated in 1999 and is based in Smyrna, Delaware.Lee Pharmaceuticals OTCMKTS:LPHM$0.01 +0.00 (+7.69%) As of 06/5/2026Lee Pharmaceuticals, Inc., through its subsidiary, RONN Motor Group, Inc., focuses on the design and development, manufacture, marketing, and sale of all-electric, hydrogen-fuel cell, and zero-emission new energy vehicles (NEVs) in the United States, China, and internationally. It intends to offer hydrogen fuel cell NEVs, including sports cars, sedans, SUVs, trucks, and buses. The company was founded in 2013 and is based in Scottsdale, Arizona. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look Amprius Insiders Are Selling: Should Investors Be Worried? MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? Planet Labs: Coming Back Down to Earth Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Nebius Is Up Nearly 175% This Year—Here's What's Driving the Latest Run Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
